Thus, reducing adipose tissue endogenous BMP inhibitors to enhance BMP4 action represents an attractive possibility to prevent obesity and increase insulin sensitivity while, in contrast, increasing these antagonists would reduce adipose tissue browning, enhance obesity and associated metabolic complications. The gene discussed is BMP4; the disease is obesity due to melanocortin 4 receptor deficiency.